⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OGN News
Organon & Co.
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS
globenewswire.com
OGN
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
OGN
New Analysis of Organon’s VTAMA ® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
businesswire.com
OGN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Investors to Connect
accessnewswire.com
OGN
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation
accessnewswire.com
OGN
Organon与Sebela Pharmaceuticals达成MIUDELLA®无激素宫内节育器授权协议
businesswire.com
OGN
Organon與Sebela Pharmaceuticals達成MIUDELLA®無荷爾蒙子宮內避孕器授權協議
businesswire.com
OGN
Organon conclut un accord pour obtenir la licence de MIUDELLA®, le dispositif intra-utérin sans hormones de Sebela Pharmaceuticals
businesswire.com
OGN
オルガノン、セベラ・ファーマシューティカルズのホルモンフリー子宮内避妊具「MIUDELLA ® 」のライセンス契約を 締結
businesswire.com
OGN
Organon schließt Lizenzvereinbarung für MIUDELLA®, das hormonfreie Intrauterinpessar von Sebela Pharmaceuticals
businesswire.com
OGN